AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10368079
Drug: Oxcarbazepine (OCBZ)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OCBZ) 1,200 mg/day
Trial: 29114894
Drug: INCS in
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INCS in monotherapy
Trial: 26575323
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg salmeterol treatment
Trial: 26575323
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg salmeterol treatment
Trial: 22581070
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (cognitive remediation + functional skills training)
Trial: 18590350
Drug: XP-828L (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP-828L (800 mg daily for 56 days)
Trial: 14628497
Drug: Androgen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen supplementation therapy (testosterone replacement therapy)
Trial: 27781372
Drug: Sufentanil Sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil Sublingual Tablet 30 mcg (SST)
Trial: 24627339
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (1 mg capsule)
Trial: 24627339
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (1 mg capsule)
Trial: 25263017
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with eGFR <30 mL/min
Trial: 25263017
Drug: VTE patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTE patients with eGFR >90 mL/min
Trial: 25263017
Drug: VTE patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTE patients with eGFR 60-89 mL/min
Trial: 25263017
Drug: VTE patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTE patients with eGFR 45-59 mL/min
Trial: 25263017
Drug: VTE patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTE patients with eGFR 30-44 mL/min
Trial: 25263017
Drug: VTE patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTE patients with eGFR 15-29 mL/min
Trial: 19202330
Drug: B-vitamin therapy
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin therapy (folic acid 2 mg, vitamin B(6) 25 mg, vitamin B(12) 0.5 mg)
Trial: 15247115
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine hydrochloride
Trial: 15247115
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine hydrochloride
Trial: 15247115
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg morphine hydrochloride
Trial: 7782117
Drug: Roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 300 mg once daily
Trial: 6367784
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg intravenously followed by 200 mg daily for three months)
Trial: 30049498
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care group without computer/tablet/smartphone (n=49)
Trial: 23112075
Drug: Tricot compression
RxNorm normalized name: Tricor
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tricot compression bandage plus intermittent cryocompression therapy 15 times for 30 minutes
Trial: 20105043
Drug: Preprandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preprandial insulin (PPI) (Exubera)
Trial: 20105043
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (BI) (insulin glargine)
Trial: 20105043
Drug: Preprandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preprandial insulin (PPI)
Trial: 15851890
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg EREM
Trial: 15851890
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg EREM
Trial: 15851890
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg EREM
Trial: 14594344
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 20 mg
Trial: 14594344
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 40 mg
Trial: 14594344
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 80 mg
Trial: 14594344
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of testosterone undecanoate
Trial: 3900303
Drug: Metoclopramide alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide alone (1.0 to 3.0 mg/kg)
Trial: 3900303
Drug: Metoclopramide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide with adjunct dexamethasone (20 mg) at a fixed dose of 2.0 mg/kg
Trial: 29197867
Drug: Topical coconut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical coconut oil (5 mL/kg) twice daily for 21 days
Trial: 29197867
Drug: Topical coconut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical coconut oil
Trial: 24576202
Drug: Ropivacaine 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.50% (50 mL)
Trial: 23027801
Drug: Algorithm-consistent warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-consistent warfarin dosing
Trial: 16969361
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily and Metformin 500 mg three times daily
Trial: 30698554
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drug therapy)
Trial: 18245148
Drug: Etanercept (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (an IgG1‐TNF p75 receptor fusion protein), administered once weekly for 12 weeks
Trial: 15291188
Drug: Diaspirin cross-linked
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaspirin cross-linked hemoglobin (DCLHb) solution (50 mg/kg or 35 mL for a 70-kg patient)
Trial: 9519099
Drug: Sulpiride (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (600 mg/day)
Trial: 8368459
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate 5.2 mg four times daily
Trial: 30198828
Drug: Yeast beta-glucan
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast beta-glucan (900 mg daily for 16 weeks)
Trial: 26835603
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) 300 mg natalizumab
Trial: 26835603
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) 300 mg natalizumab
Trial: 26835603
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) 300 mg natalizumab
Trial: 26835603
Drug: Pharmacodynamics (PD)
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacodynamics (PD) response
Trial: 22539780
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (STreSS), nine 3.5 h sessions over 4 months
Trial: 20679151
Drug: Milk naturally
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk naturally enriched in CLA (4.2%) containing c-9, t-11 providing 1.3 g/d of CLA
Trial: 20679151
Drug: Milk enriched
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk enriched with a 4.2% synthetic mixture of t-10, c-12 and c-9, t-11 CLA isomers providing 1.3 g/d of CLA
Trial: 20679151
Drug: Untreated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated milk (control) providing 0.2 g/d CLA
Trial: 17564282
Drug: 800 mcg
RxNorm normalized name: Biotin 800 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mcg nebulized beclomethasone dipropionate once daily (o.d. group)
Trial: 17564282
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg nebulized beclomethasone dipropionate twice daily (b.i.d. group)
Trial: 10419077
Drug: Felodipine-metoprolol 5/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-metoprolol 5/50 mg
Trial: 7759064
Drug: Hyperglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (blood glucose level clamped at 12.2 mmol/l for 4 hours by infusing 20% glucose solution)
Trial: 7759064
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control (isotonic saline infusion over 4 hours)
Trial: 2185694
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase without KRN 8601 treatment
Trial: 311515
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (aortocoronary bypass surgery)
Trial: 30972934
Drug: Liraglutide therapy
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide therapy for 16 weeks
Trial: 20157905
Drug: Multi-component sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component sleep therapy intervention
Trial: 12690368
Drug: Subtenons lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subtenons lidocaine injection (1 mL of 2% lidocaine)
Trial: 12690368
Drug: Subtenons lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subtenons lidocaine injection
Trial: 8889461
Drug: Pantoprazole 80
RxNorm normalized name: pantoprazole 80 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 80 mg
Trial: 8791969
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing schedules
Trial: 1620911
Drug: Modified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified formulation of inhaled salbutamol using a new inhaler device
Trial: 6391830
Drug: Trazodone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (100 to 400 mg daily)
Trial: 6391830
Drug: Mianserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (30 to 120 mg daily)
Trial: 30282447
Drug: R-CHOP-14 (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP-14 (administered every 2 weeks)
Trial: 30282447
Drug: R-CHOP-21 (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP-21 (administered every 3 weeks)
Trial: 24491414
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml kg(‐1) of 0.15% ropivacaine with 0.1 mg kg(‐1) dexamethasone (Group D)
Trial: 24491414
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml kg(‐1) of 0.15% ropivacaine (Group C)
Trial: 22348439
Drug: DHA meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA meal (high-oleic sunflower oil enriched with 4.7 g of DHA)
Trial: 22348439
Drug: EPA meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA meal (high-oleic sunflower oil enriched with 4.7 g of EPA)
Trial: 26201934
Drug: Naso-jejunal (NJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS: 20 ml/kg bolus and then 3 mL/kg/h)
Trial: 26201934
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL infusion at same rate)
Trial: 26201934
Drug: Naso-jejunal (NJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS)
Trial: 26201934
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL)
Trial: 22795809
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous bisglycinate chelate, 28 mg per day for 20 days, then 14 mg per day for 40 days (12 patients)
Trial: 22795809
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate, 105 mg per day for 60 days (12 patients)
Trial: 22795809
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events (AEs) related to treatments
Trial: 18039501
Drug: High-dose selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose selenium administration
Trial: 18039501
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of selenium
Trial: 12034949
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg intravenously)
Trial: 2254557
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment
Trial: 816842
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of disodium cromoglycate (DSCG)
Trial: 816842
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of disodium cromoglycate (DSCG)
Trial: 816842
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of disodium cromoglycate (DSCG) four times daily for 2 days
Trial: 6453695
Drug: 3% benzoyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% benzoyl peroxide gel
Trial: 6453695
Drug: 10% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 g TOPICAL SOAP [Dermaharmony 10% Benzoyl Peroxide Cleansing Bar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% benzoyl peroxide gel
Trial: 6453695
Drug: Stronger or
RxNorm normalized name: rose water,stronger ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stronger or milder concentration of benzoyl peroxide gel
Trial: 29016980
Drug: Stepped Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped Care (initial 20-min of behavioural change counselling, followed by three sessions of Motivational Enhancement Therapy and referral to local alcohol services)
Trial: 25633662
Drug: empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin 25 mg/linagliptin 5 mg
Trial: 25633662
Drug: empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin 10 mg/linagliptin 5 mg
Trial: 22474066
Drug: Torcetrapib 120
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 120 mg once daily for 4 weeks (non-atorvastatin group)
Trial: 22474066
Drug: Torcetrapib 120
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 120 mg twice daily for 4 weeks (non-atorvastatin group)
Trial: 22474066
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg daily (control group)
Trial: 9727782
Drug: Nebulized magnesium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulphate (3 mL, 3.2% solution, 95 mg)
Trial: 9727782
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (3 mL, 2.5 mg)
Trial: 3241289
Drug: Methylphenobarbital (MPB)
RxNorm normalized name: methylphenobarbital
DrugBank: Methylphenobarbital (DB00849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenobarbital (MPB) 3 x 10 mg/kg on the first day
Trial: 31822498
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg) in combination with taselisib (4 mg)
Trial: 31822498
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enzalutamide and taselisib
Trial: 25451617
Drug: Mother-infant psychoanalytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mother-infant psychoanalytic treatment (MIP group)
Trial: 16682727
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan 2.3 mg/m2/d on days 1 to 5
Trial: 16682727
Drug: Intravenous docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous docetaxel 75 mg/m2 day 1 every 21 days
Trial: 10469815
Drug: ZDV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZDV plus ddI combination therapy
Trial: 10469815
Drug: ZDV monotherapy
RxNorm normalized name: ZDV
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZDV monotherapy
Trial: 10469815
Drug: ddI monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddI monotherapy
Trial: 6849160
Drug: Disulfiram 400
RxNorm normalized name: disulfiram 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 400 mg/d
Trial: 31829248
Drug: Landiolol administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Landiolol administration for three days during the perioperative period
Trial: 29289374
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg qhs
Trial: 27754700
Drug: MPH-MLR (Methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH-MLR (Methylphenidate HCl Extended-Release)
Trial: 20537810
Drug: Gradual cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual cessation with nicotine lozenge (via mail)
Trial: 15940624
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (peginterferon and lamivudine)
Trial: 10100770
Drug: Once-daily 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Trial: 10100770
Drug: Twice-daily 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Trial: 9050699
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone (control group)
Trial: 1880221
Drug: Labetalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100 mg BID to a maximum of 400 mg BID over 6 weeks)
Trial: 1880221
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg or less BID)
Trial: 29162142
Drug: Concurrent thermochemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent thermochemoradiotherapy (HTCTRT) with locoregional hyperthermia (weekly ×6 during radiotherapy) and concurrent chemoradiotherapy (CTRT) with gemcitabine (400 mg/m2, weekly ×6)
Trial: 29162142
Drug: Chemoradiotherapy (CTRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CTRT) alone with gemcitabine (400 mg/m2, weekly ×6)
Trial: 16112720
Drug: Cocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (40 mg, IV)
Trial: 22818725
Drug: Dried apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried apple (75 g/day)
Trial: 20118174
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and sulfonylurea (n = 2227)